



King's Research Portal

DOI:

[10.1016/j.preghy.2017.12.005](https://doi.org/10.1016/j.preghy.2017.12.005)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Rocha, B. M., Mbofana, F., Loquiha, O., Mudenyanga, C., Vivian Ukah, U., Magee, L. A., & von Dadelszen, P. (2017). Early diagnosis of preeclampsia using placental growth factor: an operational pilot study in Maputo, Mozambique. *Pregnancy Hypertension*. <https://doi.org/10.1016/j.preghy.2017.12.005>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Early diagnosis of preeclampsia using placental growth factor: an operational pilot study in Maputo, Mozambique

Beatriz Manriquez Rocha, Francisco Mbofana, Osvaldo Loquiha, Chishamiso Mudenyanga, U. Vivian Ukah, Laura A. Magee, Peter von Dadelszen


PII: S2210-7789(17)30382-3
DOI: <https://doi.org/10.1016/j.preghy.2017.12.005>
Reference: PREGHY 369

To appear in: *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*

Received Date: 14 September 2017
Revised Date: 12 December 2017
Accepted Date: 23 December 2017

Please cite this article as: Rocha, B.M., Mbofana, F., Loquiha, O., Mudenyanga, C., Vivian Ukah, U., Magee, L.A., von Dadelszen, P., Early diagnosis of preeclampsia using placental growth factor: an operational pilot study in Maputo, Mozambique, *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health* (2017), doi: <https://doi.org/10.1016/j.preghy.2017.12.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Early diagnosis of preeclampsia using placental growth factor: an operational pilot study in
Maputo, Mozambique

Authors:

Beatriz Manriquez Rocha ¹

Francisco Mbofana ²

Osvaldo Loquiha ¹

Chishamiso Mudenyanga ¹

U Vivian Ukah ³

Laura A Magee ⁴

Peter von Dadelszen ⁴

Affiliations:

(1) Maternal, Newborn + Child Health, Clinton Health Access Initiative, Maputo, Mozambique

(2) National Department of Public Health, Ministry of Health, Maputo, Mozambique

(3) Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC,
Canada

(4) Department of Women's and Children's Health, School of Life Course Sciences, Faculty of
Life Sciences and Medicine, King's College London, London, United Kingdom

Short title:

Maputo pilot study of PIGF

Word count: 4771

Corresponding author:

Professor Peter von Dadelszen, Women's Health Academic Centre, 10th Floor, North Wing, St. Thomas' Hospital, Westminster Bridge Rd, Lambeth, London SE1 7EH, UK. Tel: +44 20 7188 4138; Fax: +44 20 7620 1227; email: pvd@kcl.ac.uk

ACCEPTED MANUSCRIPT

Abstract

In well-resourced settings, reduced circulating maternal free placental growth factor (PlGF) aids in either predicting or confirming the diagnosis of preeclampsia, fetal growth restriction, stillbirth, preterm birth, and delivery within 14 days of testing when pre-eclampsia is suspected. This operational pilot implementation of maternal plasma PlGF in women with suspected preeclampsia was conducted in six antenatal clinics in Maputo, Mozambique (six control clinics for comparison). The primary outcome was transfer to higher levels of care, following the informative PlGF assay. Of antenatal visits, 133/31,993 (0.42%) and 20/33,841 (0.06%) resulted in pre-eclampsia-related transfers of care for women attending intervention and control clinics, respectively ($p < 0.0001$). The clinic-to-delivery for women with low PlGF (<100 pg/ml) interval was shorter, (vs normal PlGF (median 10 days [IQR 1 - 25] vs 36 [11 - 83], $p < 0.0001$)). Low PlGF was associated with younger maternal age, higher blood pressure, earlier delivery, more therapeutic interventions, preterm birth, lower birth weight, and perinatal loss. In addition, one-third of hypertensive women with PlGF < 50 pg/ml suffered a stillbirth. In urban Mozambican women with symptoms and/or signs suggestive of preeclampsia, low maternal plasma PlGF concentrations are associated with increased risks of adverse pregnancy outcomes, especially early delivery and stillbirth. Therefore, introducing PlGF into the clinical care of women with suspected preeclampsia was associated with increased transfers to higher levels of care; low PlGF (<100 pg/ml) was associated with increased maternal and perinatal risks. PlGF <50 pg/ml is particularly associated with stillbirth in women with suspected preeclampsia.

Keywords

Preeclampsia; stillbirth; placental growth factor; diagnostic performance; operations research; global health

Introduction

Pregnancy hypertension, especially preeclampsia, remains a significant contributor to adverse maternal and perinatal events in sub-Saharan Africa (1;2). Some women whose pregnancies are complicated by preeclampsia have evidence of angiogenic factor imbalance, with a surfeit of antiangiogenic factors (e.g., soluble fms-like tyrosine kinase-1 (sFlt-1)) and reduced proangiogenic factors (e.g., placental growth factor (PlGF)) (3-7).

Previously, we have confirmed the diagnostic performance of masked plasma PlGF in identifying women at increased risk of imminent delivery in clinics in Maputo, Mozambique (8); through the identification of pregnancy complications beyond preeclampsia, such as fetal growth restriction of placental origin (9). Therefore, we have proposed that PlGF should improve the provision of precision medicine to individual women and improve pregnancy outcomes for those with preeclampsia or related placenta-mediated complications in all settings. Thereby, clinicians in all settings may be better able to triage women with suspected complications to optimize the care of those most at risk within stretched health systems.

After completion of this technical evaluation study, we designed and conducted a pilot implementation study in health centers to assess the impact of PlGF in aiding the diagnosis and time-of-disease risk stratification of preeclampsia, and, thereby, improving appropriate interventions for, and timely care of women with preeclampsia. In contrast to clinical research methods, which typically focus on the health effects of an evidence-based practice, implementation studies typically focus on rates and quality of use of evidence-based practices rather than their effects (10).

Methods

Study design and context

This operational pilot study was conducted with screening and testing of women from 26 April to 30 November 2016. In this context, the objective of this operational pilot was to assess the probable impact of large-scale implementation of an intervention, PlGF testing, within a health system.

All sites were in Maputo city, with six intervention sites (CS Bagamoyo, CS Chamanculo, CS Jose Macamo, CS Magoanine, CS 1 de Junho, CS 1 de Maio) and six control sites (CS Albazine, CS Catembe, CS Polana Canico, CS Pescadores, CS Xipamanine, CS Zimpeto). All sites offered prenatal care services, booked approximately 200 newly-identified pregnant women each month (i.e, 1400 new pregnancies per site), and had both on-site laboratory support and a maternity unit. CS Jose Macamo is associated with a general hospital. One site (CS 1 de Maio) has an ultrasound available, and CS Jose Macamo has access to the adjacent hospital's maternity unit ultrasound. The other four sites refer to the general hospital for ultrasounds, and any women referred need to use either public transport, car, or walk to get their ultrasound. Routine obstetric ultrasound was not offered at any sites, but limited to those deemed to be at high risk. Pregnancy dating was based upon last menstrual period and symphysis-fundal height. Intervention sites were matched, without randomization, to control sites based on antenatal clinic volume, maternity ward, type of support, electricity and laboratory. Referral centers were shared between intervention and control sites.

Intervention sites

All pregnant women, irrespective of age, attending the respective prenatal clinics of the six intervention sites were screened for hypertension by the attending nurse, and if any given pregnant woman <37⁺⁰ weeks' pregnant presented with any evidence preeclampsia (i.e., high BP, proteinuria, signs or symptoms) she would be a candidate for the PIGF test.

BP was measured with women sitting and with the right arm supported at the level of the heart as part of routine prenatal care, using Microlife BP A2 Basic, (Microlife AG, Widnau, Switzerland) fully automated BP monitors. BP measurement was repeated if hypertension (defined as either a systolic BP ≥ 140 mm Hg or a diastolic BP ≥ 90 mm Hg) was detected on the first reading and the lower reading recorded in the data collection form. Normotensive readings were not repeated. The presence of significant proteinuria ($\geq 2+$ by dipstick) was not an eligibility criterion.

At the time of the prenatal visit that triggered eligibility (suspected preeclampsia), venous blood was collected by the clinic nurse, plasma prepared, and PIGF assayed using the Alere

Triage[®] monoclonal antibody-based immunoassay and meter (Alere, San Diego, CA), according to the manufacturer's instructions by the on-site laboratory technician. Maternal plasma PIGF concentrations were quantified within the measurable range of the assay (12 – 3000 pg/ml) and classified as either normal (≥ 100 pg/ml) or low (< 100 pg/ml), as determined in our initial study (5). Clinical and research staff were not blinded to the PIGF results.

Pregnant women with suspected preeclampsia remained on site until the PIGF result was available and the nurse could use the result to complement diagnosis and determine whether or not to initiate a referral. If women were assessed to be too unwell to either await PIGF results, or even to have the blood draw, they were referred immediately. On occasion, the blood draw was completed, but the transport arrived prior to knowledge of the PIGF result and the woman was referred to a tertiary facility without delay.

Facility management, including delivery decisions, was made by clinicians who were not involved in the study and in compliance with Ministry of Health guidelines. The study protocol was approved by the National Bioethics Committee in Mozambique.

Patient information was collected from registries, patient charts and transfer logbooks at the prenatal care health facilities and maternity units. Dedicated study assistants were present at the intervention sites daily. They were stationed outside the antenatal clinic space and had access to all women screened for PIGF, to collect data at the time of screening. In addition, they were present when pregnant women returned for later antenatal visits or to the local maternity unit for delivery. Retrospective data were collected following delivery for women who delivered at referral maternity units. Two study assistants collected data two-to-three times a week to follow up transferred women, to ascertain whether or not they had been admitted or delivered, and the outcomes of mother and child. They attended the consulting rooms weekly, but did not interact with the women; rather, they relied solely on the available paper records (a more challenging task at referral facilities). In addition, they went weekly to search for data at referral facilities (these sites being the same referral sites for all the health centers). To support data collected from registries and patient charts, and fill in potential gaps due to deliveries occurring

in the community, pregnant women enrolled in the intervention sites were contacted via either telephone or SMS, up to two times within the month after their due date of delivery.

Control sites

In the control sites, patient information was collected from registries and transfer logbooks at the prenatal care health facilities and maternity units. Two study assistants collected data two-to-three times a week, and patient chart data, including pregnancy outcomes, were not reviewed.

Outcomes

The primary outcome for analysis was transfer to higher levels of care, following the informative PIGF assay ('clinic'). Other outcomes of interest included: median time-to-delivery, confirmed diagnosis of preeclampsia, mode of delivery, intrauterine fetal death, and preterm birth (<37⁺⁰ weeks). For outcome adjudication, preeclampsia was defined as hypertension and either significant proteinuria or other maternal organ dysfunction, according to the 2014 ISSHP criteria (11). Adjudication of a diagnosis of preeclampsia was performed by obstetricians not involved in the women's care but taking into consideration the PIGF results.

Sample size

The sample size was determined considering that the pilot was a two-arm multi-site observational cohort, with six health facilities in each of the intervention and control arms. Assuming that PIGF would be able to diagnose about 25% more cases in the intervention sites than conventional care in the control sites (above a baseline prevalence of 35% in women with suspected preeclampsia in control sites), the sample size required for 80% power and 5% significance was 106 in each arm.

Statistical approach

Statistical analyses: Kaplan-Meier curves were derived and Mantel-Cox log-rank test survival analyses performed to describe the primary outcome. Fisher's exact and chi-square tests were used for categorical variables and Mann-Whitney U tests were used for continuous variables.

To assess the performance of PIGF to identify women who suffered an intrauterine fetal death, an area under the receiver-operator curve (AUC ROC) analysis was performed. Using Prism 5.0 (GraphPad, San Diego, CA), statistical significance was set at $p < 0.05$ for the primary comparison, and $p < 0.01$ for other comparisons (to adjust for multiple comparisons).

Results

During the seven months of the study, the diagnosis of preeclampsia was suspected in 278 and 194 women in intervention and control sites, respectively. These represent 0.87% of 31,993 and 0.57% of 33,841 antenatal visits in intervention and control sites, respectively (Yate's-corrected χ^2 $p < 0.0001$; relative risk 1.21 (95% confidence interval (CI) 1.13 - 1.31). In addition, this represents a 3.3% detection rate (assuming 8400 women receiving prenatal care in the six intervention sites), compared with a 2.3% (194/8400 women) suspected preeclampsia rate in six control sites (Yate's-corrected χ^2 $p = 0.0001$; relative risk 1.23 (95% CI 1.09 - 1.37)). Fetal heart sounds were detected using Pinard stethoscopes in all women at eligibility.

Maternal transfer to higher levels of care (primary outcome) was initiated for 133/278 (47.8%) and 20/194 (10.3%) of women in intervention and control sites, respectively (Yates-corrected χ^2 $p = 0.0001$; relative risk 1.91 (95% CI 1.67 - 2.19)). These represent referral rates of 0.42% and 0.06% of antenatal visits in intervention and control sites, respectively (Yate's-corrected χ^2 $p < 0.0001$; relative risk 1.79 (95% CI 1.68 - 1.91).

Table 1 describes the baseline characteristics and outcomes of the 278 women with suspected preeclampsia attending for prenatal care at the intervention sites. Compared with 148 women with normal PIGF (≥ 100 pg/ml), the 130 women with low PIGF (< 100 pg/ml) were younger, at later gestational age when screened for PIGF, more severely hypertensive, more likely to have a confirmed diagnosis of preeclampsia by either proteinuria or symptoms, especially symptomatic preeclampsia, and more likely to have an increased number of prenatal visits (all $p < 0.01$); they tended to be more often nulliparous ($p = 0.0180$) and receive antihypertensive medication ($p = 0.0191$). This detail of clinical data was not available for the women who attended the control sites.

In terms of the clinic-to-delivery interval, women with low PIGF delivered more quickly (median: 10 days) compared with those with normal PIGF (median: 36 days) (Figure 1(a)). Women with low PIGF delivered at earlier gestational ages (35 vs 37 weeks, respectively (Figure 1(b))), more frequently preterm (85% vs 55%, respectively), and lighter infants (2.5 kg vs 3.1 kg, respectively). Only two (0.7%) women in this cohort received antenatal corticosteroids, although 117 of 278 (42.1%) women delivered before 35⁺⁰ weeks of pregnancy. Of the 160 (of 242 women who received antihypertensive agents) for whom the antihypertensive agents were recorded, 33 received solely methyldopa, while three received methyldopa and nifedipine, 100 received methyldopa and hydralazine and 21 received methyldopa, nifedipine and hydralazine. Three women received solely hydralazine.

There were three maternal deaths, two were women with normal PIGF (one of whom declined early referral to hospital and arrived moribund; the other declined to remain an inpatient and was lost to local follow-up (moved to South Africa)) and one with low PIGF (in-facility death in the regional tertiary hospital). Twenty-three percent of women with low PIGF suffered an intrauterine fetal death, compared with 6% of women with normal PIGF ($p < 0.0001$). Neonatal survival was similar between groups.

The area under the receiver-operator curve analysis of the performance determined that maternal PIGF predicted both intrauterine fetal death (AUC ROC = 0.78) and perinatal death (AUC ROC = 0.75) (Figure 2). Thirty of 92 (32.6%) women with PIGF < 50 pg/ml suffered an intrauterine fetal death, compared with nine of 177 (5.1%) women with PIGF ≥ 50 pg/ml (Yates-corrected χ^2 $p < 0.0001$). Using that cut-off of < 50 pg/ml, maternal plasma PIGF has a sensitivity of 76.9% (95% CI 60.7% - 88.9%) and specificity of 74.1% (95% CI 68.0% - 79.5%) in the prediction of intrauterine fetal death.

Discussion

In this implementation study, we have determined that among women with preeclampsia who attended prenatal clinics in Maputo, Mozambique, the introduction of a package of care, including the use of PIGF, was associated with both an increased detection of preeclampsia and an increased number of transfers of care. In addition, low maternal plasma PIGF identified

women destined to deliver soon and have more complicated pregnancies, as determined previously using masked PIGF results (8). Also, we have determined that maternal plasma PIGF <40 - 50 pg/ml identifies a group of women at exceptionally high risk for suffering an intrauterine fetal death (32.6% of women with PIGF <50 pg/ml).

The incidence of suspected preeclampsia in intervention sites was as anticipated from the literature (12); it is almost certain that the diagnosis was missed in a number of women in control sites. Due to probable incomplete identification of women with suspected preeclampsia in the control sites, direct comparison of the performance of the PIGF assay in terms of reducing the incidence of preeclampsia-related adverse pregnancy outcomes could not be assessed. However, women in the intervention sites were almost twice as likely to be referred to higher levels of care than were women in control sites. The identification of women with pregnancies complicated by preeclampsia and responding to precision risk assessment using PIGF, as achieved in the intervention sites, are critical steps towards reducing direct maternal deaths due to pregnancy hypertension (13).

Incomplete knowledge of the detailed clinical characteristics and outcomes of women who attended for prenatal visits in the control sites is the major limitation of this pragmatic operational pilot study. In addition, the level of confidence in these results might have been improved had a stepped-wedge implementation trial design been used (14).

The exact threshold for raising specific intrauterine fetal death concern requires specific hypothesis-driven research in both general populations and targeted high-risk populations (e.g., preeclampsia, fetal growth restriction, previous intrauterine fetal death) of women. If testing for maternal PIGF can be converted into a whole blood point-of-care assay, we believe that there is great potential for this biomarker of the imperfectly performing placenta to be used at scale to reduce the burden of intrauterine fetal death. Currently, in less-developed settings without access to sophisticated Doppler ultrasound, we believe that a maternal plasma PIGF <50 pg/ml should be considered as a strong indication for initiating delivery.

Although the median number of prenatal care visits was the same in women with normal and low PIGF (median number of visits: 3), there was a significant increase in the number of visits in

the low PIGF group as a whole ($p=0.0006$). This is likely to be due to an appropriate response by the woman and her care providers' knowledge about her low PIGF status, although these low PIGF women remained pregnant for about one-third of the time (median: 14 days) than did women with normal PIGF (median: 41 days).

Two hundred and forty-two (87.1%) women with suspected preeclampsia in the intervention cohort received antihypertensive agents, with a trend for more in the low PIGF group ($p = 0.0191$). This probably reflects higher systolic and diastolic blood pressure readings at the recruitment prenatal visit. However, as any severe hypertension confers as much risk to a pregnancy as the diagnosis of preeclampsia (15), blood pressure should be normalized in all pregnancies complicated by hypertension, using the CHIPS Trial tight control decision algorithm (16). In settings such as these, in which all three delays that contribute to maternal death are operating, tight control (i.e., targeting a diastolic blood pressure of 85 mm Hg, and responding to any systolic blood pressure ≥ 160 mm Hg) is likely to have benefits beyond those observed in the main CHIPS Trial. Four hundred and sixty-three of the 981 women in CHIPS developed preeclampsia. The preferential use of methyldopa is consistent with knowledge of availability, cost, improved pregnancy outcomes and neurodevelopmental reassurance to seven years of age (16-19).

Although known to be the optimal agent for both the prevention and treatment of eclampsia (20-23), there was very low use of magnesium sulfate in this cohort (4.7% of hypertensive women overall), even though care providers were informed of the PIGF results, and low PIGF is known to identify women at greater risk for adverse events (5;8;9). It is incumbent on those introducing such a new package of care to ensure vertical integration of the health system and that effective messaging around the new technology crosses all levels of the health system to modify caregiving behavior. Unfortunately, we were not able to determine with certainty the incidence of eclampsia within the cohort. Therefore, whether or not low PIGF should be a specific indication for magnesium sulfate use remains uncertain.

The low rate of use of antenatal corticosteroids (0.7%) in this cohort of women is consistent with the findings in our previous Maputo-based study (8) in which only two of 494 women

(0.4%) who delivered prior to 35⁺⁰ weeks received corticosteroids (data previously unpublished). Knowledge of low PIGF status did not change the behavior of care providers between the two studies. It should be noted that the Mozambique Ministry of Health has only recently actively implemented the use of antenatal corticosteroids for fetal lung maturation (train-the-trainers workshop, June 5-7, 2017). In addition, the publication of the ACT cluster-randomized trial in 2015 (24) may have impeded corticosteroid use in this setting where most women have somewhat uncertain dates.

Perspectives

There has been increasing evidence for the role of time-of-disease maternal plasma PIGF in identifying incremental maternal and perinatal risks in pregnancies complicated by placental disorders (i.e, preeclampsia, fetal growth restriction and a large proportion of intrauterine fetal death), including in the similar settings in Maputo. To our knowledge, this is the first study to assess the impact of PIGF on clinical practice and outcomes in a less-developed country setting. We have identified that introducing PIGF into clinical care in antenatal clinics is associated with increased identification of women who are deemed to require transfer to higher levels of care. In addition, we have confirmed the ability of low PIGF, measured at time-of-disease, to identify women with pregnancies complicated by preeclampsia who are at increased risk of adverse events. Also, we have identified that a PIGF threshold of 40 – 50 pg/ml identifies a group of hypertensive pregnant women with a one-third risk of losing their fetus to stillbirth. This requires elucidation. This operational pilot provides additional insights to support the creation of a manual of procedures and recommendations for the scale up of the PIGF test to support the time-of-disease assessment of women with suspected preeclampsia, and screening for stillbirth risk, in high-risk pregnancies in Mozambique.

Acknowledgements

We wish to acknowledge Suraia Marcarenhas (General Nurse) and Valdemira Alda Andrade (Maternal Child Health Nurse) for their roles in day-to-day data gathering and clinical site support. In addition, we wish to thank the clinical advisory board: Professor David Hall (Stellenbosch University), Professor James M Roberts (Magee Women's Research Institute, University of Pittsburgh), Professor Andrew Shennan (King's College London), Dr Augusto Cesar Macome (Hospital Central da Beira).

ACCEPTED MANUSCRIPT

Sources of funding:

The authors are grateful for project funding received from the Government of Flanders (PIGF testing) and Irish Aid Mozambique. We gratefully acknowledge the donation of Microlife AG BP devices and batteries, and urinary dipsticks by the Clinton Health Access Initiative, Maputo.

ACCEPTED MANUSCRIPT

Disclosures

P. von Dadelszen has been a paid consultant to Alere International. The other authors report no conflicts.

ACCEPTED MANUSCRIPT

Reference List

- (1) Mol BW, Roberts CT, Thangaratinam S, Magee LA, de Groot CJ, Hofmeyr GJ. Pre-eclampsia. *Lancet* 2016 March 5;387:999-1011.
- (2) Say L, Chou D, Gemmill A, Tunçalp O, Moller AB, Daniels J et al. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health* 2014 June;2(6):e323-e333.
- (3) Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. *Am J Obstet Gynecol* 2011 November;205(5):469-e1-8.
- (4) Bramham K, Seed PT, Lightstone L, Nelson-Piercy C, Gill C, Webster P et al. Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. *Kidney Int* 2016 April;89(4):874-85.
- (5) Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. *Circulation* 2013 November 5;128(19):2121-31.
- (6) Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N Engl J Med* 2006 September 7;355(10):992-1005.
- (7) Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW et al. Redefining preeclampsia using placenta-derived biomarkers. *Hypertension* 2013 May;61(5):932-42.
- (8) Ukah UV, Mbofana F, Rocha BM, Loquiha O, Mudenyanga C, Usta M et al. Diagnostic performance of placental growth factor in women with suspected preeclampsia attending antenatal facilities in Maputo, Mozambique. *Hypertension* 2017 March;69(3):469-74.
- (9) Benton SJ, McCowan LM, Heazell AE, Gynspan D, Hutcheon JA, Senger C et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. *Placenta* 2016 June;42:1-8.
- (10) Bauer MS, Damschroder L, Hagedorn H, Smith J, Kilbourne AM. An introduction to implementation science for the non-specialist. *BMC Psychol* 2015 September 16;3:32.
- (11) Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. *Pregnancy Hypertens* 2014 April;4(2):97-104.
- (12) Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. *Best Pract Res Clin Obstet Gynaecol* 2011 August;25(4):391-403.
- (13) von Dadelszen P, Magee LA. Pre-eclampsia: an update. *Curr Hypertens Rep* 2014 August;16(8):454.

- (14) Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. *BMJ* 2015 February 6;350:h391.
- (15) Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S et al. The CHIPS randomized controlled trial (Control of Hypertension in Pregnancy Study): is severe hypertension just an elevated blood pressure? *Hypertension* 2016 November;68(5):1153-9.
- (16) Magee LA, von DP, Rey E, Ross S, Asztalos E, Murphy KE et al. Less-tight versus tight control of hypertension in pregnancy. *N Engl J Med* 2015 January 29;372(5):407-17.
- (17) Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. *Lancet* 1982 March 20;1(8273):647-9.
- (18) Lalani S, Firoz T, Magee LA, Sawchuck D, Payne B, Gordon R et al. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. *J Obstet Gynaecol Can* 2013 March;35(3):215-23.
- (19) Magee LA, von DP, Singer J, Lee T, Rey E, Ross S et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. *BJOG* 2016 June;123(7):1143-51.
- (20) Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for eclampsia. *Cochrane Database Syst Rev* 2010 December 8;(12):CD000127.
- (21) Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev* 2010 November 10;(11):CD000025.
- (22) Duley L, Henderson-Smart DJ, Chou D. Magnesium sulphate versus phenytoin for eclampsia. *Cochrane Database Syst Rev* 2010 October 6;(10):CD000128.
- (23) Duley L, Gulmezoglu AM, Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. *Cochrane Database Syst Rev* 2010 September 8;(9):CD002960.
- (24) Althabe F, Belizan JM, McClure EM, Hemingway-Foday J, Berrueta M, Mazzoni A et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. *Lancet* 2015 February 14;385(9968):629-39.

Highlights

- In urban health centers in Mozambique, introducing PIGF for precision assessment of maternal risks increased referrals of women with preeclampsia to higher levels of care.
- Low PIGF (<100 pg/ml) identifies women at increased risk of adverse maternal and perinatal events
- Stillbirth complicates preeclampsia pregnancies approximately one-third of the time when PIGF <50 pg/ml.
- All women in the study were hypertensive with suspected preeclampsia.
- PIGF values were revealed to the clinical staff as an element of clinical assessment.

ACCEPTED MANUSCRIPT

Figure legends

Figure 1. (a) Time from clinic-to-delivery by placental growth factor concentration dichotomized between normal placental growth factor (≥ 100 pg/ml; median 10 days (blue)) and low placental growth factor (< 99 pg/ml; median 36 days (red)). (b) Gestational age at delivery by placental growth factor concentration dichotomized between normal placental growth factor (≥ 100 pg/ml; median 37 weeks) and low placental growth factor (< 99 pg/ml; median 35 weeks).


Figure 2. Area under the receiver operator curve for placental growth factor in predicting intrauterine fetal death (IUFD; purple) and perinatal mortality up to 28 days (PNM; blue). A maternal plasma placental growth factor concentration < 41.8 pg/ml has 76.92% (95% confidence interval (CI) 60.67% - 88.87%) sensitivity, 78.2% (95% CI 72.5% - 83.3%) specificity, with a positive likelihood ratio (LR+) of 3.54 for intrauterine fetal death, and PIGF < 39.7 pg/ml a 66.7% (95% CI 52.1% - 79.2%) sensitivity, 79.7% (73.9% - 84.8%) specificity and LR+ of 3.29 for perinatal mortality.

ACCEPTED MANUSCRIPT


Table 1. Baseline characteristics and outcomes (n (%) or median (interquartile range))

Characteristic	Intervention sites		P-value
	PIGF \geq 100 pg/mL (n = 148)	PIGF < 100pg/mL (n = 130)	
Baseline characteristics			
Maternal age, yr	29 (24 – 34)	27 (22 – 31)	0.0061
Nulliparous, Y	28 (18.9)	41 (31.5%)	0.0180
Maternal weight, kg	70 (62 – 80) (n=146)	71 (62 – 79) (n=127)	0.6944
Twin pregnancy, Y	2 (1.4%)	7 (5.4%)	0.0875
Gestational age at recruitment, wk	30 (25 – 34)	33 (29 – 35)	0.0002
Blood pressure at recruitment			
systolic blood pressure, mmHg	150 (142 – 162)	157 (146 – 172)	0.0004
diastolic blood pressure, mmHg	94 (90 – 100)	101 (94 – 111)	<0.0001
Preeclampsia, Y	135 (91.2%)	130 (100%)	0.0002
proteinuria \geq 1+	32 (21.6%)	67 (51.5%)	<0.0001
preeclampsia symptoms, Y	102 (74.9%)	112 (88.2%)	0.0021
preeclampsia symptoms, n	1 (0 – 2)	2 (1 -3)	<0.0001
New diagnosis of HIV in this pregnancy, Y	39 (21.3%)	30 (19.6%)	0.7865
Serum PIGF, pg/mL	355 (186 – 828)	25.8 (\leq 12.0 – 58.9)	<0.0001


Interventions received			
Number of prenatal visits, n	3 (1 – 4)	3 (2 – 5)	0·0006
Antihypertensive(s), Y	122 (82·4%)	120 (92·3%)	0·0191
Magnesium sulfate, Y	11 (7·4%)	12 (9·2%)	0·6650
Antiretrovirals, Y	72 (48·6%)	77 (59·2%)	0·0917
Dexamethasone, Y	1 (0·7%)	1 (0·8%)	1·0000
Pregnancy outcomes			
Clinic-to-delivery interval, d	36 (11 – 83)	10 (1 – 25)	<0·0001
Gestational age at delivery, wk	37 (34 – 40)	35 (32 – 36)	<0·0001
Preterm birth, Y	81 (54·7%)	110 (84·6%)	<0·0001
Cesarean delivery, Y	41 (27·7%)	43 (33·1%)	0·3608
Birth weight, kg	3·1 (2·7 – 3·4) (n=134)	2·5 (2·0 – 3·0) (n=108)	<0·0001
Maternal mortality, Y	2 (1·4%) (missing = 13)	1 (0·8%) (missing =7)	1·0000
Perinatal and late neonatal mortality, Y	14 (9·6%)	37 (28·5%)	<0·0001
intrauterine fetal death, Y	9 (6·1%)	30 (23·1%)	<0·0001
neonatal death <28d, Y	5 (3·6%) (n=139)	7 (7·0%) (n=100)	0·2475



ACCEPTED



ACCEPT



ACC

Highlights

- In urban health centers in Mozambique, introducing PIGF for precision assessment of maternal risks was associated with increased referrals of women with preeclampsia to higher levels of care.
- Low PIGF (<100 pg/ml) identifies women at increased risk of adverse maternal and perinatal events
- Stillbirth complicates preeclampsia pregnancies approximately one-third of the time when PIGF <50 pg/ml.
- All women in the study were hypertensive with suspected preeclampsia.
- PIGF values were revealed to the clinical staff as an element of clinical assessment.

ACCEPTED MANUSCRIPT